A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)
The Journal of Infectious Diseases2010Vol. 201(4), pp. 600–607
Citations Over TimeTop 10% of 2010 papers
Hannah Kibuuka, Robert Kimutai, Leonard Maboko, Fred Sawe, Mirjam Schunk, Arne Kroidl, Douglas Shaffer, Leigh Anne Eller, Rukia Kibaya, Michael A. Eller, K. Schindler, Alexandra Schuetz, Monica Millard, Jason R. Kroll, Len Dally, Michael Höelscher, Robert T. Bailer, Josephine H. Cox, Mary Marovich, Deborah L. Birx, Barney S. Graham, Nelson L. Michael, Mark de Souza, Merlin L. Robb
Abstract
The DNA/rAd5 vaccination regimen was safe and induced HIV type 1 multi-clade T cell responses, which were not significantly affected by titers of preexisting rAd5 neutralizing antibody. Trial Registration. ClinicalTrials.gov identifier: NCT00123968 .
Related Papers
- → Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse(2001)74 cited
- → Chicken IL-7 as a potent adjuvant enhances IBDV VP2 DNA vaccine immunogenicity and protective efficacy(2016)22 cited
- → Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model(2009)24 cited
- Development of SARS-CoV vaccines and evaluation of their immunogenicity(2008)
- The Effect of Codon Optimization on the Immunogenicity of DNA Vaccine(2011)